Breaking News

Amgen CFO Steps Down

By Kristin Brooks | January 10, 2014

Kelly to fill role on an interim basis

Jonathan M. Peacock, executive vice president and chief financial officer, is leaving Amgen to pursue other opportunities. Mr. Peacock will be stepping down from his role on January 10, and will remain with the company to assist with the transition. Michael A. Kelly has been named acting chief financial officer, reporting to Robert A. Bradway, chairman and chief executive officer.
 
"Since joining Amgen over three years ago, Jon has played an important role in developing and implementing the company's strategy for growth and in delivering value for shareholders," said Mr. Bradway. "We thank Jon for his many contributions and fully support his desire to pursue broader opportunities."
 
Mr. Kelly will be responsible for the company's finance and investor relations operations. He joined Amgen in 2003 and has served in several executive finance roles, including five years as chief accounting officer and more recently as chief financial officer for international commercial operations. Prior to joining the company, he held finance roles at Tanox, Biogen and Monsanto Life Sciences.
 
"Michael Kelly is an experienced financial executive," said Mr. Bradway.  "I am delighted to have him reporting to me as acting CFO while we search for Jon's successor."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks